Stockwatch: The Victimization Of Big Biotech
Early Success In Biotech Raises An Almost Impossible Bar
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
You may also be interested in...
Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.